Cite
HARVARD Citation
Marconi, V. et al. (2021). Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet. 9 (12), pp. 1407-1418. [Online].